States are rethinking how virtual manufacturers and wholesalers should be licensed.

Is your compliance strategy keeping up?

The pharmaceutical industry has embraced a business model that would have seemed almost impossible a generation ago. Today a company can develop a product, own the intellectual property, oversee commercialization, manage supply chain strategy, and distribute product nationally without operating a single manufacturing facility or warehouse of its own.

Virtual manufacturers and virtual wholesalers have fundamentally changed the way pharmaceutical businesses operate. They offer flexibility, scalability, lower overhead, and faster market entry. For many emerging pharmaceutical companies, the model is not just attractive; it is essential.

But while the industry has evolved quickly, state licensing frameworks have struggled to keep pace.

Across the country, regulators are beginning to reassess how these businesses fit into existing licensing structures. States that once viewed pharmaceutical operations strictly through the lens of brick-and-mortar facilities are now confronting a very different reality: companies directing manufacturing, storage, and distribution activities remotely while relying heavily on contract partners and third-party logistics providers.

For regulatory and licensing teams managing these operations, the landscape is becoming increasingly complex.

The Rise of the Virtual Pharmaceutical Company

As we discussed in our previous article, “A Revolution in Medicine, a Maze of Regulations,” virtual operating models have become one of the fastest-growing structures in the pharmaceutical space. Companies are increasingly relying on CMOs, contract packagers, third-party logistics providers, and wholesale partners to support product manufacturing and distribution while maintaining lean internal infrastructures.

The advantages are obvious. Companies can reduce operational costs, accelerate commercialization timelines, scale more efficiently, and gain access to specialized expertise without investing in large physical footprints. For startups and emerging pharmaceutical organizations especially, the virtual model can create opportunities that would otherwise be financially out of reach.

The regulatory side, however, is far less straightforward.

Most state licensing laws were originally designed around physical possession of prescription drugs and oversight of fixed facilities. As a result, many licensing frameworks do not neatly align with modern virtual business structures. The ambiguity has left licensing and compliance teams navigating a patchwork of interpretations that often differ significantly from one state to another.

For some companies, the central question becomes whether a virtual entity should be licensed as a manufacturer, a wholesaler, or both. Others are trying to determine whether the use of a 3PL changes their licensing obligations, or whether they can rely on the licenses held by contract partners handling physical product operations.

The challenge is that there is rarely a universal answer.

Illinois Highlights an Emerging Regulatory Trend

One of the clearest recent examples of this evolving landscape is unfolding in Illinois.

Illinois has introduced legislation that would amend the state’s Wholesale Drug Distribution Licensing Act to establish a formal licensing category for virtual wholesale distributors. The proposed framework would require certain virtual entities to obtain licensure even when they do not physically possess prescription drugs themselves.

This development is important because it reflects a broader shift in regulatory thinking. States are increasingly moving beyond the traditional concept that only physical handlers of product require oversight. Regulators are beginning to focus more heavily on operational control, supply chain responsibility, and the companies directing pharmaceutical commerce behind the scenes.

In other words, a company may face licensing obligations not because it stores or ships products directly but because it controls the commercial activities tied to those products.

That distinction matters tremendously for modern pharmaceutical organizations.

Many virtual companies oversee supplier selection, quality management, inventory decisions, distribution authorization, product ownership, and trading partner relationships while outsourcing the physical handling functions entirely. Regulators are recognizing that these companies still play a central role in the integrity of the pharmaceutical supply chain.

Illinois may ultimately become a model that other states look to as they modernize their own licensing frameworks.

For companies operating under virtual models, these developments create both operational and compliance risks.

Many organizations built their licensing strategies years ago when state expectations surrounding virtual operations were far less defined. Since then, business models have evolved rapidly while regulatory interpretations have continued shifting in the background.

That creates the potential for dangerous gaps between a company’s current operations and its existing licensing posture.

A seemingly minor licensing issue can quickly create larger consequences, including delays in product launches, distribution interruptions, audit findings, trading partner concerns, and even disciplinary exposure in certain jurisdictions. The risks become even more significant when companies operate nationally and must navigate fifty different interpretations of what constitutes regulated activity.

At the same time, states are asking more sophisticated questions during licensing reviews and enforcement matters. Regulators are looking closely at who owns the product, who controls distribution decisions, who manages quality oversight, and how supply chain responsibilities are allocated among virtual entities and their contract partners.

Even states that have not formally established virtual licensing categories are beginning to scrutinize these operational structures more aggressively. For licensing portfolio managers this means historical assumptions may no longer be reliable.

The Industry Is Moving Faster Than the Regulations

One of the biggest challenges facing virtual pharmaceutical companies is that regulatory modernization is happening unevenly.

Some states are proactively updating statutes and regulations to specifically address virtual operations. Others continue relying on older laws while interpreting them more broadly to capture evolving business models. In many jurisdictions, guidance remains informal, inconsistent, or entirely absent.

That uncertainty creates a difficult environment for compliance leaders attempting to build scalable licensing strategies that will hold up long term. A structure that appears compliant today could face entirely different expectations tomorrow as states continue revisiting wholesale distribution and manufacturing oversight requirements.

The broader direction, however, is becoming increasingly clear. Regulators want greater visibility into who is controlling pharmaceutical supply chain activity, regardless of whether they physically touch the product.

Preparing for What Comes Next

For virtual pharmaceutical companies, now is the time to proactively reevaluate licensing strategies rather than waiting for enforcement actions or operational disruptions to expose potential gaps.

Organizations should be reviewing whether their current licenses accurately align with their real-world business activities, how different states classify their operational role, and whether outsourced manufacturing or logistics arrangements create additional obligations that may not have existed when the company was originally licensed.

In many cases, companies discover that their operations have evolved significantly over time while their licensing assumptions have remained unchanged.

That disconnect can become increasingly problematic as states continue modernizing their regulatory frameworks and taking a closer look at virtual business models.

The pharmaceutical industry’s transition toward virtual operations is not slowing down. If anything, it is accelerating. The efficiencies and flexibility these structures provide make them highly attractive in an increasingly competitive market.

But with that evolution comes heightened regulatory attention.

The companies that will be best positioned moving forward are the ones that recognize licensing strategy can no longer be treated as a static administrative function. As states continue redefining how virtual manufacturers and wholesalers are regulated, proactive compliance management will become an increasingly important competitive advantage.